GlassScriptPhysician profile
Charles E Zierenberg
NPI 1114992948
$3,494.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2021: $2,557 · 2022: $21.37 · 2023: $289 · 2024: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,316.85 | 2019-2021 | |
| Acumed LLC | $1,295.34 | 2019-2021 | |
| Smith+Nephew, INC. | $195.39 | 2019-2023 | Evos, Evos Mini, R3 Acetabular |
| Johnson and Johnson International | $130.30 | 2019-2023 | Healix Knotless Peek, Truespan Orthocord |
| Medartis INC. | $104.80 | 2024 | Aptus |
| Janssen Pharmaceuticals, INC | $100.00 | 2019 | |
| Pacira Therapeutics, INC. | $89.37 | 2019-2021 | |
| Medtronic USA, INC. | $89.15 | 2019 | |
| Melinta Therapeutics, LLC | $49.15 | 2019 | |
| Skeletal Dynamics INC | $48.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.75 | 2019 | |
| Vericel Corporation | $21.37 | 2022 | |
| Organogenesis INC. | $18.16 | 2023 | Puraply |
| Amgen INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Zierenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.